| Parameter |
Total population |
No cardiac |
Cardiac Inflammation |
Significance |
| |
|
Inflammation |
|
|
| n |
29 |
6 |
23 |
|
| Age (years) |
48 ± 16 |
48 ± 15 |
51 ± 14 |
n.s. |
| Male gender |
16(55%) |
4(67%) |
12(52%) |
n.s. |
| NYHA class |
4/14/8/2 |
1/4/1/0 |
3/10/7/2 |
n.s. |
| (I/II/III/IV), % |
(14/48/27/7) |
(17/67/17/0) |
(13/44/30/9) |
|
| Cardiac risk factors |
|
|
|
|
| Smoking |
8 (28%) |
3(50%) |
4 (17%) |
n.s. |
| Diabetes mellitus |
1 (3%) |
0 |
1 (4%) |
n.s. |
| Hypercholesterinaemia |
11(38%) |
1(17%) |
10(44%) |
n.s |
| Arterial Hypertension |
16(55%) |
4(67%) |
12(52%) |
n.s. |
| Medication |
|
|
|
|
| ACE-Inhibitors/AT1-blocker |
16(55%) |
4(67%) |
10(44%) |
n.s. |
| ß-blocker |
19(66%) |
3(50%) |
13(57%) |
n.s. |
| Statins |
6 (21%) |
1(17%) |
4 (17%) |
n.s. |
| Haemodynamic and echocardiographic measurements |
|
|
|
|
| LVEF (%) |
52 ± 16 |
58 ± 22 |
49 ± 15 |
0.16 |
| LVEDD (mm) |
55.3 ± 8.1 |
51.6 ± 6.13 |
59.78 ± 11 |
0.04 |
| Laboratory parameters |
|
|
|
|
| Leukocyte count (/nl)) |
7.3 ± 2.3 |
6.4 ± 1.6 |
7.3 ± 1.9 |
n.s. |
| Hs-CRP (mg/dl) |
1.9 ± 5.2 |
1.2 ± 1.8 |
2.1 ± 6.1 |
n.s. |
| NT-proBNP (pg/ml) |
949 ± 1901 |
890 ± 949 |
1089 ± 2097 |
n.s. |
| Endomyocardial biopsy |
|
|
|
|
| CD3 (/mm2) |
18.8 ± 55.6 |
4 ± 2 |
23± 61 |
0.04 |
| LFA-1 (/mm2) |
27.5 ± 56.6 |
7 ± 2 |
33 ± 63 |
n.a |
| HLA (AF%) |
8.9 ± 5.0 |
7 ± 2 |
9 ± 6 |
n.s. |
NYHA: dyspnoea according to The New York Heart Association; LVEF: left
ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter; hs-
CRP: high sensitivity C-reactive protein; CD3: T- lymphocytes; LFA: lymphocyte
function-associated antigen-1, CD11a; HLA: human leukocyte antigen; AF: area
fraction. Significant (p-values) are given for subgroup analyses. |
